Structure Therapeutics Inc.
41.23USD
+0.8500 (+2.10%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.24▼ | $-0.19 | 1 | 6 |
| Next quarter | $-0.49▼ | $-0.45 | 2 | 5 |
| Current year | $-1.64▼ | $-1.43 | 0 | 9 |
| Next year | $-2.18▼ | $-2.08 | 1 | 7 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.38 | $-0.49 | -0.11 (-28.3%) |
| 2026-03-31 | $-0.31 | $-0.35 | -0.04 (-12.9%) |
| 2025-12-31 | $-0.37 | $0.2 | +0.57 (+154.2%) |
| 2025-09-30 | $-0.37 | $-0.37 | -0.00 (-0.6%) |
60 ratings from 16 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Citigroup | Maintained | Buy | $100 $97 | Aug 7, 2026 |
| Citizens | Maintained | Market Outperform | $113 $110 | Aug 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100 $70 | Jun 11, 2026 |
| Canaccord Genuity | Initiated | Buy | $101 | Apr 27, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $114 $100 | Mar 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $90 $114 | Mar 2, 2026 |
| Citizens | Maintained | Market Outperform | $120 $113 | Feb 27, 2026 |
| JP Morgan | Maintained | Overweight | $65 $105 | Jan 22, 2026 |
| Guggenheim | Maintained | Buy | $90 $140 | Jan 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60 $90 | Dec 19, 2025 |
| Morgan Stanley | Maintained | Overweight | $120 $125 | Dec 12, 2025 |
| Citizens | Maintained | Market Outperform | $87 $120 | Dec 12, 2025 |
| Jefferies | Maintained | Buy | $79 $125 | Dec 11, 2025 |
| Citigroup | Maintained | Buy | $60 $100 | Dec 9, 2025 |
| Stifel | Maintained | Buy | $50 $90 | Dec 9, 2025 |
| Clear Street | Maintained | Buy | $61 $99 | Dec 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $75 $60 | Aug 7, 2025 |
| Guggenheim | Maintained | Buy | $92 $90 | Aug 7, 2025 |
| JMP Securities | Maintained | Market Outperform | $89 $87 | Aug 7, 2025 |
| Cantor Fitzgerald | Reiterated | Overweight | $65 | Jun 23, 2025 |
| JMP Securities | Reiterated | Market Outperform | $89 | Jun 23, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $80 $75 | May 12, 2025 |
| Citigroup | Initiated | Buy | $60 | May 2, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $80 | Apr 22, 2025 |
| Citizens Capital Markets | Maintained | Market Outperform | $91 $87 | Feb 28, 2025 |
24 filings from 8 insiders · 0 buy / 0 sell over 6m
Officers and directors of GPCR, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| LIN XICHENOfficer | Exercise | 11.8k | $0.34 | $4k | Aug 18, 2026 |
| BERRIOS JOHN JOSEPHOfficer | Grant | 140.8k | — | — | Aug 6, 2026 |
| LIN XICHENOfficer | Exercise | 11.8k | $0.34 | $4k | Aug 4, 2026 |
| LIN XICHENOfficer | Exercise | 23.6k | $50.59 | $1.20M | Jul 14, 2026 |
| LIN XICHENOfficer | Exercise | 23.6k | $0.34 | $8k | Jun 25, 2026 |
| LANG MATTHEWChief Operating Officer | Grant | 184.6k | — | — | Apr 15, 2026 |
| COLL CRESPO BLASOfficer | Grant | 75.9k | — | — | Mar 19, 2026 |
| YOON JUNChief Financial Officer | Grant | 104.1k | — | — | Mar 19, 2026 |
| LIN XICHENOfficer | Grant | 43.4k | — | — | Mar 19, 2026 |
| MA YINGLIChief Technology Officer | Grant | 32.5k | — | — | Mar 19, 2026 |
| HALL ASHLEYOfficer | Grant | 47.7k | — | — | Mar 19, 2026 |
| STEVENS RAYMOND CChief Executive Officer | Grant | 260.2k | — | — | Mar 19, 2026 |
| COLL CRESPO BLASOfficer | Grant | 8.0k | — | — | Jul 1, 2025 |
| YOON JUNChief Financial Officer | Grant | 39.6k | — | — | Jul 1, 2025 |
| LIN XICHENOfficer | Grant | 57.1k | — | — | Jul 1, 2025 |
| MA YINGLIChief Technology Officer | Grant | 24.5k | — | — | Jul 1, 2025 |
| STEVENS RAYMOND CChief Executive Officer | Grant | 89.7k | — | — | Jul 1, 2025 |
| COLL CRESPO BLASOfficer | Grant | 117.0k | — | — | Mar 14, 2025 |
| YOON JUNChief Financial Officer | Grant | 170.2k | — | — | Mar 14, 2025 |
| LIN XICHENOfficer | Grant | 80.8k | — | — | Mar 14, 2025 |
No analyst notes on GPCR yet.
Analyst Ratings
15 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 11 | 1 | 0 | 0 | Buy1.81 |
| 1 mo ago | 4 | 11 | 1 | 0 | 0 | Buy1.81 |
| 2 mo ago | 4 | 11 | 1 | 0 | 0 | Buy1.81 |
| 3 mo ago | 4 | 12 | 1 | 0 | 0 | Buy1.82 |